Aspergillus precipitating antibody in patients with Mycobacterium avium complex lung disease: A cross-sectional study

Shoji Suzuki, Takanori Asakura, Ho Namkoong, Satoshi Okamori, Kazuma Yagi, Hirofumi Kamata, Yoshifumi Uwamino, Yohei Funatsu, Yasushi Nakano, Tomoyasu Nishimura, Makoto Ishii, Tamotsu Ebihara, Tomoko Betsuyaku, Naoki Hasegawa

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Rationale: Little is known about the role of Aspergillus precipitating antibody (APAb) in patients with Mycobacterium avium complex lung disease (MAC-LD). Objectives: We investigated the clinical characteristics of patients with MAC-LD positive for APAb. Methods: We conducted a cross-sectional study targeting patients with MAC-LD. APAb was checked in all participants. Clinical variables included laboratory data, pulmonary function, high-resolution computed tomography findings, and health-related quality of life. Results: We analyzed 109 consecutive patients. Their median age was 68 years, and the median duration of MAC-LD was 4.8 years. Twenty (18.3%) patients tested positive for APAb. APAb-positive patients had significantly longer duration of MAC-LD (9.4 vs. 4.0 years, P = 0.017), more severe bronchiectasis evaluated by modified Reiff score (6.5 vs. 4, P = 0.0049), and lower forced expiratory volume in 1 s (%FEV1) (75.1% vs. 86.2%, P = 0.013) than APAb-negative patients. Analysis of covariance adjusted for background factors and underlying pulmonary disease revealed that %FEV1 was also significantly lower in patients with APAb (P = 0.045). Ten patients were newly diagnosed with chronic pulmonary aspergillosis (N = 5) or allergic bronchopulmonary aspergillosis (N = 5). Conclusions: APAb is associated with lower pulmonary function, and observed especially in patients with longer duration of MAC-LD and severe bronchiectasis, even in the absence of cavitary lesions.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalRespiratory Medicine
Volume138
DOIs
Publication statusPublished - 2018 May 1

Fingerprint

Mycobacterium avium Complex
Aspergillus
Lung Diseases
Cross-Sectional Studies
Antibodies
Bronchiectasis
Allergic Bronchopulmonary Aspergillosis
Pulmonary Aspergillosis
Lung
Forced Expiratory Volume
Tomography
Quality of Life

Keywords

  • Allergic bronchopulmonary aspergillosis (ABPA)
  • Aspergillus precipitating antibody
  • Bronchiectasis
  • Chronic pulmonary aspergillosis (CPA)
  • Mycobacterium avium complex (MAC)

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Aspergillus precipitating antibody in patients with Mycobacterium avium complex lung disease : A cross-sectional study. / Suzuki, Shoji; Asakura, Takanori; Namkoong, Ho; Okamori, Satoshi; Yagi, Kazuma; Kamata, Hirofumi; Uwamino, Yoshifumi; Funatsu, Yohei; Nakano, Yasushi; Nishimura, Tomoyasu; Ishii, Makoto; Ebihara, Tamotsu; Betsuyaku, Tomoko; Hasegawa, Naoki.

In: Respiratory Medicine, Vol. 138, 01.05.2018, p. 1-6.

Research output: Contribution to journalArticle

Suzuki, Shoji ; Asakura, Takanori ; Namkoong, Ho ; Okamori, Satoshi ; Yagi, Kazuma ; Kamata, Hirofumi ; Uwamino, Yoshifumi ; Funatsu, Yohei ; Nakano, Yasushi ; Nishimura, Tomoyasu ; Ishii, Makoto ; Ebihara, Tamotsu ; Betsuyaku, Tomoko ; Hasegawa, Naoki. / Aspergillus precipitating antibody in patients with Mycobacterium avium complex lung disease : A cross-sectional study. In: Respiratory Medicine. 2018 ; Vol. 138. pp. 1-6.
@article{a9ad5736b8dd4025949ec834b0ebbe30,
title = "Aspergillus precipitating antibody in patients with Mycobacterium avium complex lung disease: A cross-sectional study",
abstract = "Rationale: Little is known about the role of Aspergillus precipitating antibody (APAb) in patients with Mycobacterium avium complex lung disease (MAC-LD). Objectives: We investigated the clinical characteristics of patients with MAC-LD positive for APAb. Methods: We conducted a cross-sectional study targeting patients with MAC-LD. APAb was checked in all participants. Clinical variables included laboratory data, pulmonary function, high-resolution computed tomography findings, and health-related quality of life. Results: We analyzed 109 consecutive patients. Their median age was 68 years, and the median duration of MAC-LD was 4.8 years. Twenty (18.3{\%}) patients tested positive for APAb. APAb-positive patients had significantly longer duration of MAC-LD (9.4 vs. 4.0 years, P = 0.017), more severe bronchiectasis evaluated by modified Reiff score (6.5 vs. 4, P = 0.0049), and lower forced expiratory volume in 1 s ({\%}FEV1) (75.1{\%} vs. 86.2{\%}, P = 0.013) than APAb-negative patients. Analysis of covariance adjusted for background factors and underlying pulmonary disease revealed that {\%}FEV1 was also significantly lower in patients with APAb (P = 0.045). Ten patients were newly diagnosed with chronic pulmonary aspergillosis (N = 5) or allergic bronchopulmonary aspergillosis (N = 5). Conclusions: APAb is associated with lower pulmonary function, and observed especially in patients with longer duration of MAC-LD and severe bronchiectasis, even in the absence of cavitary lesions.",
keywords = "Allergic bronchopulmonary aspergillosis (ABPA), Aspergillus precipitating antibody, Bronchiectasis, Chronic pulmonary aspergillosis (CPA), Mycobacterium avium complex (MAC)",
author = "Shoji Suzuki and Takanori Asakura and Ho Namkoong and Satoshi Okamori and Kazuma Yagi and Hirofumi Kamata and Yoshifumi Uwamino and Yohei Funatsu and Yasushi Nakano and Tomoyasu Nishimura and Makoto Ishii and Tamotsu Ebihara and Tomoko Betsuyaku and Naoki Hasegawa",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/j.rmed.2018.03.013",
language = "English",
volume = "138",
pages = "1--6",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Aspergillus precipitating antibody in patients with Mycobacterium avium complex lung disease

T2 - A cross-sectional study

AU - Suzuki, Shoji

AU - Asakura, Takanori

AU - Namkoong, Ho

AU - Okamori, Satoshi

AU - Yagi, Kazuma

AU - Kamata, Hirofumi

AU - Uwamino, Yoshifumi

AU - Funatsu, Yohei

AU - Nakano, Yasushi

AU - Nishimura, Tomoyasu

AU - Ishii, Makoto

AU - Ebihara, Tamotsu

AU - Betsuyaku, Tomoko

AU - Hasegawa, Naoki

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Rationale: Little is known about the role of Aspergillus precipitating antibody (APAb) in patients with Mycobacterium avium complex lung disease (MAC-LD). Objectives: We investigated the clinical characteristics of patients with MAC-LD positive for APAb. Methods: We conducted a cross-sectional study targeting patients with MAC-LD. APAb was checked in all participants. Clinical variables included laboratory data, pulmonary function, high-resolution computed tomography findings, and health-related quality of life. Results: We analyzed 109 consecutive patients. Their median age was 68 years, and the median duration of MAC-LD was 4.8 years. Twenty (18.3%) patients tested positive for APAb. APAb-positive patients had significantly longer duration of MAC-LD (9.4 vs. 4.0 years, P = 0.017), more severe bronchiectasis evaluated by modified Reiff score (6.5 vs. 4, P = 0.0049), and lower forced expiratory volume in 1 s (%FEV1) (75.1% vs. 86.2%, P = 0.013) than APAb-negative patients. Analysis of covariance adjusted for background factors and underlying pulmonary disease revealed that %FEV1 was also significantly lower in patients with APAb (P = 0.045). Ten patients were newly diagnosed with chronic pulmonary aspergillosis (N = 5) or allergic bronchopulmonary aspergillosis (N = 5). Conclusions: APAb is associated with lower pulmonary function, and observed especially in patients with longer duration of MAC-LD and severe bronchiectasis, even in the absence of cavitary lesions.

AB - Rationale: Little is known about the role of Aspergillus precipitating antibody (APAb) in patients with Mycobacterium avium complex lung disease (MAC-LD). Objectives: We investigated the clinical characteristics of patients with MAC-LD positive for APAb. Methods: We conducted a cross-sectional study targeting patients with MAC-LD. APAb was checked in all participants. Clinical variables included laboratory data, pulmonary function, high-resolution computed tomography findings, and health-related quality of life. Results: We analyzed 109 consecutive patients. Their median age was 68 years, and the median duration of MAC-LD was 4.8 years. Twenty (18.3%) patients tested positive for APAb. APAb-positive patients had significantly longer duration of MAC-LD (9.4 vs. 4.0 years, P = 0.017), more severe bronchiectasis evaluated by modified Reiff score (6.5 vs. 4, P = 0.0049), and lower forced expiratory volume in 1 s (%FEV1) (75.1% vs. 86.2%, P = 0.013) than APAb-negative patients. Analysis of covariance adjusted for background factors and underlying pulmonary disease revealed that %FEV1 was also significantly lower in patients with APAb (P = 0.045). Ten patients were newly diagnosed with chronic pulmonary aspergillosis (N = 5) or allergic bronchopulmonary aspergillosis (N = 5). Conclusions: APAb is associated with lower pulmonary function, and observed especially in patients with longer duration of MAC-LD and severe bronchiectasis, even in the absence of cavitary lesions.

KW - Allergic bronchopulmonary aspergillosis (ABPA)

KW - Aspergillus precipitating antibody

KW - Bronchiectasis

KW - Chronic pulmonary aspergillosis (CPA)

KW - Mycobacterium avium complex (MAC)

UR - http://www.scopus.com/inward/record.url?scp=85044150759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044150759&partnerID=8YFLogxK

U2 - 10.1016/j.rmed.2018.03.013

DO - 10.1016/j.rmed.2018.03.013

M3 - Article

C2 - 29724379

AN - SCOPUS:85044150759

VL - 138

SP - 1

EP - 6

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

ER -